Demand for swine flu vaccines below original forecasts is threatening to slow the growth in predicted revenues for four of Europe's leading pharmaceuticals companies,
GlaxoSmithKline, Sanofi-Aventis, Novartis and AstraZeneca. A number of academic studies in recent weeks have shown that most people require a single dose of vaccine in order to acquire protection, compared with the two doses originally believed necessary and used in orders by governments including the UK. Financial Times, December 18, 2009 Swine flu threat still receding Almost 3.5m people have now been vaccinated against swine flu as the disease continues to decline, according to government figures released yesterday. Overall cases and hospital admissions were down, but the proportion of patients in critical care increased slightly. There have now been an estimated 800,000 cases and 203 deaths in England. Financial Times, December 18, 2009